






INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 265/30, 498/04	A1	(11) International Publication Number: WO 90/14342 (43) International Publication Date: 29 November 1990 (29.11.90)
(21) International Application Number: PCT/SE90/00323 (22) International Filing Date: 14 May 1990 (14.05.90) (30) Priority data: 8901838-6 24 May 1989 (24.05.89) SE 8901837-8 24 May 1989 (24.05.89) SE (71) Applicant (for all designated States except US): PHARMACIA AB [SE/SE]; S-721 82 Uppsala (SE). (72) Inventors; and (75) Inventors/Applicants (for US only) : HERNESTAM, Sven [SE/SE]; Ekbackegatan 40, S-212 30 Malmö (SE). THELIN, Bernt [SE/SE]; Råbyvägen 15 C, S-223 57 Lund (SE). SEIFERT, Elisabeth [SE/SE]; Andreas Rydelius väg 3, S-223 66 Lund (SE). NILSSON, Arne [SE/SE]; Sergels väg 13 C, S-217 57 Malmö (SE).		(74) Agent: THYLÉN, Eva; Leo AB, Box 941, S-251 09 Helsingborg (SE). (81) Designated States: AT, AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES, ES (European patent), FI, FR (European patent), GB (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), SU, US. Published <i>With international search report.</i>
(54) Title: SUBSTITUTED ISOXAZOLIDINES AND ISOXAZOLINES		
<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>IV-anti</p> </div> <div style="text-align: center;">  <p>IV-syn</p> </div> <div style="text-align: center;">  <p>V</p> </div> <div style="margin-left: 20px;"> <p>(A)</p> </div> </div>		
(57) Abstract The invention concerns a new process for preparing delmopinol using intermediates having formula (A) wherein R is 2-propylpentyl optionally with one, two or three internal unsaturated bonds, or 2-substituted-2-propylpentyl optionally with one or two internal unsaturated bonds wherein the 2-substituent is a leaving group.		

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

SUBSTITUTED ISOXAZOLIDINES AND ISOXAZOLINES

Preparation process

The present invention concerns a new process for the preparation of delmopinol (recINN) as well as new intermediates used in the process.



delmopinol


Delmopinol is a compound which has shown promising results as a plaque inhibitor. It is therefore intended to be used as an ingredient in e.g. mouthrinses and toothpastes. Delmopinol is a morpholino compound which is described in US patent 4,636,382. This patent also describes several manufacturing methods that can be used for the preparation of this type of morpholino compounds. Up to now delmopinol has been prepared in large scale and in acceptable yields according to a process comprising 16 steps. It is obvious that this manufacturing process is both time and labour consuming. It is therefore an urgent need to provide a manufacturing process that is less time and labour consuming but still gives acceptable yields also in a large scale.

The present invention provides a solution to this problem.

Summary of the invention


According to the invention the intermediate isoxazolidines (IV) and isoxazolines (V) and delmopinol, 3-(4-propylheptyl)-4-morpholine-ethanol is prepared by a process comprising the following steps:

- a) Preparation of mono- and polyunsaturated 4-propylheptyl compounds I and II, with a terminal olefinic or acetylenic bond.




wherein R is 2-propylpentyl optionally having one, two or three internal unsaturated bonds, or 2-substituted-2-propylpentyl optionally having one or two internal unsaturated bonds, wherein the 2-substituent is a leaving group.


- b) Reacting mono- and polyunsaturated 4-propylheptyl compounds (I and II) with morpholine nitron (III)




to produce the compounds IV or V.



IV-anti



IV-syn




V


R is as defined for compounds I and II

- c) Reductive ringopening of the compounds IV and V to the compounds VIa, VIb and VIc having the formulas:


3



VIa



VIb



VIc

- d) Transferring VIb and VIc to the corresponding chloro-analogs.
- e) Transferring the compounds of step d) to the compound VIa and
- f) Alkylating the compound VIa to 3-(4-propylpentyl)-morpholine-ethanol (delmopinol).

The mono- and polyunsaturated 4-propylheptyl compounds I and II are prepared according to examples 1-5.

The leaving group in step a) can be any of usual leaving groups and is suitably selected from hydroxy, alkoxy, acetoxy or tetrahydropyranyloxy.

The morpholine nitron III, used in step b) can be prepared from N-hydroxymorpholine by oxidation with e.g. yellow mercuric oxide, palladium and other oxidants, or from the same precursor by photochemical or electrochemical oxidation. It may also be prepared directly from morpholine by oxidation with

2-(phenylsulfonyl)-3-phenyloxaziridine or by catalytic oxidation using hydrogen peroxide and a catalyst, e.g. selenium dioxide or sodium tungstate.

The morpholine nitron is too unstable to be isolated and is thus used directly for reaction with the unsaturated compounds I and II.

The compounds IV-anti and IV-syn (as racemates) are produced according to examples 6-12 in acceptable yields, and the unreacted starting material is easy to recover and recycle in the process. The compounds formed are diastereomers where IV-anti accounts for 90-98% and IV-syn for 2-10%. The stereochemistry of the adducts is based on analogy. See e.g. C. Hootelé et al., Bull.Soc.Chim.Belg., 1987, 96, 57 and references cited therein. The stereochemistry of compounds IV, as well as the degree of unsaturation, is not of importance in view of the total synthesis. All compounds IV converge to the same final product through the following steps.

Step c) can be carried out by treatment of compound IV and V, preferably with an acid e.g. p-toluenesulfonic acid, in a lower alcohol, preferably isopropanol, in a reductive milieu. This consists of a catalyst, preferably Pd-C, under H₂-pressure, preferably 3-7 atm.

Step d) is performed by reacting the reaction mixture from step c) with a chlorinating agent, preferably by boiling with thionyl chloride.

In step e) the compounds from step d) are dechlorinated by hydrogenation, preferably with Raney-Ni as catalyst.

In step f) finally, the compound VIa is alkylated, preferably by treatment with chloroethanol and potassium iodide and, at intervals, potassium hydroxide to give the desired 3-(4-propylheptyl)-4-morpholine-ethanol.

The most important aspect of this invention concerns the intermediates IV and V, as defined in the claims, and the preparation thereof, as these are key intermediates in the process for producing delmopinol.

The invention is further illustrated by the following

examples, of which 1-5 concerns the preparation of the terminal alkenes/alkynes. Examples 6-12 concerns the preparation of isoxazolidines (IV) and isoxazolines (V), and examples 13-15 the final preparation of delmopinol.

EXAMPLES

Example 1

Preparation of 4-propyl-1-heptene (Ia)

To 100 g of 4-propylheptyl bromide in 400 ml of benzene was added 90 g of t-BuOK in 300 ml of DMSO. The temperature was kept below 50°C during the addition. The mixture was stirred for 2 hrs and 600 ml of water was added. The organic phase was separated and the aqueous phase extracted with petroleum ether (b.p. 40-60°). The combined organic phases were washed with water and brine. After drying with Na₂SO₄ and evaporation the residue was distilled. Yield: 23.2 g (b.p. 56-59°C/75 Torr). ¹H-NMR(CDCl₃): δ 0.9(6H,CH₃), 1.2(9H,CH₂,CH), 2.0(2H,CH₂C=C), 4.8-5.1(2H,CH₂=C), 5.5-6.0(1H,CH=C)

Example 2

Preparation of 4-propyl-1,3-heptadiene (Ib) and cis/trans-4-propyl-1,4-heptadiene (Ic)

To 80 g of PBr₃ in 250 ml of dry diethyl ether was slowly added 46 g of 4-hydroxy-4-propyl-1-heptene at -30°C to -20°C. After the addition the temperature was kept at -25°C to -10°C another 2 hrs and then at +5°C for 15 hrs. The reaction mixture was poured on ice (500 g) and diethyl ether (500 ml) was added. The ether phase was separated and washed with NaHCO₃-solution (2X250 ml), dried with MgSO₄ and evaporated. The residue (60.0 g) was taken up in 250 ml of benzene and 94 g of 1,8-diazabicyclo[5.4.0]undec-7-ene(1,5-5) and refluxed for 2 hrs. After cooling 1000 ml of diethyl ether was added and the ether solution washed with 5M HCl (2X300 ml) and water (3X250 ml), dried with MgSO₄ and evaporated. The residue (38.2 g) was

distilled and the fraction 48-56°C/8 Torr was 30.6 g. GC showed that it was composed of 47% of cis/trans-4-propyl-1,4-heptadiene (not separated) and 46% of 4-propyl-1,3-heptadiene. The 1,4- and 1,3-isomers were separated by preparative gas-liquid chromatography (Perkin Elmer F21) on a 12 m X 8 mm column with 20% Carbowax 20M, 180°C and 1.9 atm nitrogen pressure.

$^1\text{H-NMR}(\text{CDCl}_3)$:

Ib: δ 0.9(6H, CH₃), 1.3-1.5(4H, CH₂CC=C), 1.9-2.2(4H, CH₂C=C),
4.9-5.1(2H, CH₂=C), 5.8-5.9(1H, C=CHC=C), 6.5-6.7(1H, C=CCH=C)

Ic: δ 0.8-0.9(6H, CH₃), 1.3-1.5(2H, CH₂CC=C), 1.9-2.1(4H, CH₂C=C),
2.6-2.8(2H, C=CCH₂C=C), 4.9-5.1(2H, CH₂=C), 5.1-5.3(1H, CH=C),
5.6-5.9(1H, CH=C)

Example 3

Preparation of 4-hydroxy-4-propyl-1-heptene (Id)

113 g of 4-heptanone in 1000 ml of dry diethyl ether was slowly added to a solution of allylmagnesium bromide, prepared from 36.5 g of Mg and 178 g of allyl bromide in 500 ml dry diethyl ether. After the addition the mixture was refluxed for 10 hrs. The reaction mixture was poured on a mixture of 150 g ice, 450 ml of 20% NH₄Cl and 350 ml of 5M HCl. The ether phase was separated and the water phase extracted with diethyl ether (3x100 ml). The combined organic phases were then washed with a Na₂CO₃-solution and water, dried with Na₂SO₄ and evaporated. The residue was distilled. Yield: 142 g (b.p. 38-40°C/0.1 torr)
 $^1\text{H-NMR}(\text{CDCl}_3)$: δ 0.9(6H, CH₃), 1.3-1.6(9H, CH₂, OH), 2.1-2.3 (CH₂C=C), 5.0-5.2(CH₂=C), 5.6-6.1(CH=C)

Example 4

Preparation of 2-propylpentyl tosylate

To a mixture of 52 g 2-propylpentanol and 86 g of p-toluenesulfonic acid in 175 ml of chloroform was added at 0-3°C and under N₂-atmosphere 48 g of pyridine. The mixture was kept at 0°C for 30 minutes and at room temperature for 19 hrs. After cooling the reaction mixture, 3M HCl (300 ml) was added. The organic phase was separated and washed with water and

brine. Drying with Na_2SO_4 and evaporation gives 110 g of 2-propylpentyl tosylate.

$^1\text{H-NMR}(\text{CDCl}_3)$: δ 0.8(6H, CH_3), 1.1-1.8(9H, CH_2 , CH), 2.4(3H, ArCH_3), 3.9(2H, OCH_2), 7.2-7.9(4H, ArH)

Example 5

Preparation of 4-propyl-1-heptyne (IIa)

18.4 g of lithium acetylide ethylenediamine complex was charged in an argon-flushed flask. DMSO was then added (100 ml) and the mixture cooled to 15°C . 50 g of 2-propylpentyl p-toluenesulfonate was slowly added. After the addition the mixture was stirred at room temperature for 1 hr and then 50 ml of water was added carefully with vigorous stirring (the temperature was kept below 35°C). The mixture was poured into 600 ml of water and extracted with hexane (3X100 ml). The combined hexane phases were washed with brine and dried with Na_2SO_4 . The hexane was distilled off and the residue distilled at reduced pressure. Yield 13.1 g (b.p $75-80^\circ\text{C}/85$ Torr).

$^1\text{H-NMR}(\text{CDCl}_3)$: δ 0.9(6H, CH_3), 1.3(9H, CH_2 , CH), 1.9(1H, $\text{CH}\equiv\text{C}$), 2.2(2H, $\text{CH}_2\text{C}\equiv\text{C}$)

Example 6


General procedure for preparation of isoxazolidines (IV) and isoxazoline (V) (method A)

To a mixture of the terminal alkene/alkyne (10 g), morpholine (19 g) and $\text{Na}_2\text{WO}_4 \cdot 2\text{H}_2\text{O}$ (2.7 g) in methanol (50 g) and ethanol (50 g) was added 35% H_2O_2 (43 g) at a rate to keep the temperature at $50-60^\circ\text{C}$. Additional ethanol (100 ml) was added and the mixture kept at $50-60^\circ\text{C}$ for 18 hrs. Most of the methanol/ethanol was evaporated in vacuo whereupon water (300 ml) was added and the mixture extracted with diethyl ether (4X50 ml). The organic phase was washed with water and brine. Drying with Na_2SO_4 and evaporation gives the isoxazolidines(IV)/isoxazoline(V).

(Other combinations of solvents are possible e.g with CHCl_3 , toluene and CH_2Cl_2 .)

Example 7Preparation of isoxazolidine IVd (method A)

70 g of 35% H_2O_2 was added to a mixture of 31 g of morpholine, 125 ml of methanol, 125 ml of ethanol, 19 g of 4-hydroxy-4-propyl-1-heptene and 4.8 g of $Na_2WO_4 \cdot 2H_2O$ at a rate to keep the temperature at 50–80°C. An additional amount of 200 ml of ethanol was added and the mixture was kept at 50–60°C for 18 hrs. Most of the methanol/ethanol was evaporated in good vacuum, whereupon 600 ml of water was added and the mixture was extracted with ether (4x200 ml). The ether phase was treated with 5M HCl (4x100 ml) and 13.5 g of the starting material was recovered. The acidic aqueous phase was alkalized and extracted with ether. Drying with Na_2SO_4 and evaporation gave 5.9 g of IVd (90% anti + 10% syn).



IVd

Example 8Preparation of isoxazolidine IVd (method B)

735 g of 30% H_2O_2 was added to 330 g of morpholine and 52 g of $Na_2WO_4 \cdot 2H_2O$ in 400 ml of water, slowly under cooling. The temperature of the reaction mixture was kept below 20°C. One half of this nitron mixture was then added to a refluxing mixture of 100 g of 4-hydroxy-4-propyl-1-heptene and 900 ml of methanol. After the addition refluxing was continued for 2.5 hrs whereupon the second half of the nitron mixture was added and refluxing continued for another 2.5 hrs. After cooling the mixture was extracted with toluene (750 ml). The toluene mixture was extracted with 5M HCl (650 ml). From the organic phase 57 g of starting material, 4-hydroxy-4-propyl-1-heptene,









was recovered. The aqueous phase was adjusted to pH 8.8 with 5M NaOH and extracted with toluene (500 ml). After drying with Na_2SO_4 and evaporation 37 g of IVd was recovered as syn-anti mixture.

Examples 9-12

Further examples 9-12 were prepared pursuant to the process described in Example 6. These are presented in table I.

In Example 12 the product (Va) has not been isolated in pure form. Yield has been determined by $^1\text{H-NMR}$ (CDCl_3): δ 0.9(6H, CH_3), 1.3(9H, CH_2 , CH), 4.5(1H, $\text{CH}=\text{C}$). The product can be used as intermediate in subsequent reactions without giving any byproducts.

Table I

Example	Unsaturated compound	Product	Yield ¹⁾ (%)	Ratio ²⁾ syn/anti
9	 Ia	 IVa	10	3:97
10	 Ib	 IVb	60	10:90
11	 Ic	 IVc	24	3:97 ³⁾
12	 IIa	 Va	12	-

1) Yields are not optimized.

2) The stereochemistry of the adduct is based on analogy. See e.g C. Hootelé et al., Bull.Soc.Chim.Belg., 1987, 96, 57 and references cited therein.

3) Compound IVc are formed as a 50:50 mixture of cis- and trans-isomers, where the syn-anti ratio of each is approx. 3:97.

Example 13Reductive ringopening of isoxazolidine IVd

A mixture of 10 g of isoxazolidine IVd, 27 g of p-toluene-sulfonic acid and 1.5 g of 10% Pd-C in 100 ml of isopropanol was shaken in a Parr bottle at 70-80°C and 3-7 atm of H₂ for 15 hrs. After cooling, the reaction mixture was filtered and the isopropanol was evaporated in a good vacuum. An excess of 5M NaOH was added and the mixture was extracted with diethyl ether. After drying and evaporation 8.8 g of a mixture of VIa, VIb and VIc (R= 2-propylpentyl) was recovered.

Example 14Chlorination of hydroxyalkyl morpholines VIb and VIc (R= 2-propylpentyl) and subsequent dechlorination

15 ml of thionyl chloride was added to 5.0 g of a mixture of compounds VIa, VIb and VIc (R= 2-propylpentyl) in 7 ml of chloroform and the mixture was stirred at 20°C for 3 hrs and refluxed for 1 hr. After evaporation 5M NaOH (25 ml) was added and the mixture was extracted with diethyl ether (3x15 ml). The combined ether phases were washed with water and brine. Drying and evaporation gave 4.8 g of the chloro-analogs and VIa.

This mixture, together with 5 g of Raney-Ni catalyst, 5 g of triethylamine and 250 ml of dioxane, was hydrogenated at 100°C and 120 atm of H₂ for 24 hrs. The reaction mixture was filtered through Celite and evaporated. 30 ml of 5M NaOH was added and the mixture extracted with diethyl ether (3x15 ml). After drying and evaporation 4.3 g of pure 3-(4-propylheptyl)-morpholine was recovered.


Example 15Preparation of 3-(4-propylheptyl)-4-morpholine-ethanol

A mixture of 2.5 g of 3-(4-propylheptyl)morpholine, 3.5 g of chloroethanol, 1.1 g of potassium iodide and 7 ml of ethanol was refluxed for 5 hrs. Then 0.3 g of KOH in 1.5 ml of ethanol was added and refluxing continued for 2 hrs when another 0.2 g

of KOH in 1.0 ml of ethanol was added. Refluxing for 7 hrs was followed by a third addition of 0.1 g of KOH in 0.5 ml of ethanol. After another 2 hrs of refluxing the solvent was evaporated and 10 ml of water was added. The mixture was extracted with diethyl ether (3x10 ml) and the combined organic phases were washed with brine. After drying and evaporation 2.5 g of 3-(4-propylheptyl)-4-morpholine-ethanol was recovered.


CLAIMS

1. a) Process for the preparation of delmopinol comprising reacting a mono- or polyunsaturated 4-propylheptyl compound having the formula I or II:




wherein R is 2-propylpentyl optionally with one, two or three internal unsaturated bonds, or 2-substituted-2-propylpentyl optionally having one or two internal unsaturated bonds wherein the 2-substituent is a leaving group;

- b) reacting the mono- and polyunsaturated 4-propylheptyl compound (I and II) with a morpholine nitro-
ne (III)




III


to produce the compounds IV or V:



IV-anti




IV-syn




V

wherein R is a previously defined;


- c) reductive ringopening of the compounds IV and V to the compounds VIa, VIb and VIc having the formulas:



VIa




VIb




VIc


- d) transferring VIb and VIc to the corresponding chloroanalogs;
 - e) transferring the compounds of step d) to the compound VIa and
 - f) alkylating the compound VIa to delmopinol (3-(4-propylpentyl)-morpholine-ethanol).
2. Process according to claim 1 characterized in that the leaving group is selected from hydroxy, alkoxy, acetoxy or tetrahydropyranyloxy.
 3. Process according to claim 1 characterized in that the unsaturated compound has formula I and that R is 2-propylpentyl, 2-propyl-1-pentenyl, 2-propyl-2-pentenyl or 2-hydroxy-2-propylpentyl.
 4. Process according to claim 1 characterized in that the unsaturated compound has formula II and that R is 2-propylpentyl.
 5. Intermediates having the formulas:



IV-anti



IV-syn



V

wherein R is 2-propylpentyl optionally with one, two or three internal unsaturated bonds, or 2-substituted-2-propylpentyl optionally with one or two internal unsaturated bonds wherein the 2-substituent is a leaving group.

6. Intermediates according to claim 5 characterized in that the leaving group is selected from hydroxy, alkoxy, acetoxy or tetrahydropyranyloxy.
7. Intermediates according to claim 5 characterized in that it has formula IV wherein R is 2-propylpentyl, 2-propyl-1-pentenyl, 2-propyl-2-pentenyl or 2-hydroxy-2-propylpentyl.
8. Intermediates according to claim 5 characterized in that it has formula V wherein R is 2-propylpentyl.

INTERNATIONAL SEARCH REPORT

International Application No PCT/SE 90/00323

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC5: C 07 D 265/30, 498/04		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC5	C 07 D	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched ⁸		
SE,DK,FI,NO classes as above		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	EP, A1, 0038785 (AB FERROSAN) 28 October 1981, see the whole document --	1-8
A	DE, C2, 3406805 (DER PRÄSIDENT DER OSAKA UNIVERSITY) 13 September 1984, see the whole document --	1-8
A	Bulletin des sociétés chimiques belges, Vol. 96, 1987 C. Hootelé et al.: "The cycloaddition reaction between styrene and 2,3,4,5-tetrahydropyridine 1-oxide", see page 57 --	1-8
A	J. Chem. Soc., Chem. Commun., Vol., 1984 Hitoshi Mitsui et al.: "Tungstate Catalysed Oxidation of Secondary Amines with Hydrogen Peroxide. A Novel Transformation of Secondary Amines into Nitrones", see page 874 -- -----	1-8
<p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
15th August 1990	1990 -08- 1 6	
International Searching Authority	Signature of Authorized Officer	
SWEDISH PATENT OFFICE	Irja Berlin <i>Irja Berlin</i>	

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.PCT/SE 90/00323**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on **90-06-27**. The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A1- 0038785	81-10-28	AU-B- 543919	85-05-09
		AU-D- 6858481	81-09-24
		BE-A- 888052	81-07-16
		CA-A- 1154769	83-10-04
		CH-A-B- 662352	87-09-30
		DE-A- 3110796	82-01-28
		FR-A-B- 2478636	81-09-25
		GB-A-B- 2073180	81-10-14
		JP-C- 1241489	84-11-26
		JP-A- 56156271	81-12-02
		JP-B- 59014463	84-04-04
		LU-A- 83244	83-02-22
		NL-A- 8101383	81-10-16
		SE-B-C- 439011	85-05-28
		SE-A- 8002218	81-09-22
		US-A- 4636382	87-01-13
DE-C2- 3406805	84-09-13	GB-A-B- 2136422	84-09-19
		JP-C- 1353752	86-12-24
		JP-A- 59164762	84-09-17
		JP-B- 61019623	86-05-17
		US-A- 4596874	86-06-24